Novogen, a US-Australian drug development company, has appointed Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive as Acting Chief Executive until a permanent appointment is made.
Former CEO Dr Graham Kelly has decided to leave the company to resume his work in non-oncology based early stage research.
Ross is currently Chairman of Premier Veterinary Group (formerly Ark Therapeutics), a Non-executive Director of Amarantus Bioscience Holdings and a Non-executive Director at ASX-listed companies Anatara Lifesciences, Benitec Biopharma and Tissue Therapies.
Following a career with multinational companies, Sandoz, Hoffman La Roche and Celltech Group, Ross has over the past 20 years undertaken a number of company start-ups, turnarounds and exits as a Board member on behalf of private equity groups and banks.
Ross said. 'Novogen has an outstanding team of scientists, a strong management group and an experienced and committed Board of Directors. My goal in the short term is to bring focus and clarity to the organisation, while finding the best person to lead the company going forward. We intend to keep shareholders fully informed during this transition.'
